^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Title:

Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors

Excerpt:
Sequencing of ALK kinase domain revealed that a single mutation became predominant at high crizotinib doses in each cell line, namely L1196Q and I1171N in Karpas-299 and SUP-M2 cells, respectively. These mutations also conferred resistance to crizotinib in Ba/F3 cells expressing human NPM-ALK.
DOI:
10.1158/1541-7786.MCR-12-0569